ライフサイエンスコーパス: monophosphoryl

1 The macaques were boosted with SIV gp120 in monophosphoryl A-stable emulsion adjuvant at 24 and 36 w

2 responsible for the formation of decaprenyl-monophosphoryl-beta-D-arabinose (DPA) in the genome of M

3 ng the sugar donor beta-d-arabinofuranosyl-1-monophosphoryl-decaprenol (DPA) and a newly synthesized

4 zing the sugar donor beta-D-mannopyranosyl-1-monophosphoryl-decaprenol together with the neoglycolipi

5 t transfer the 2'-azido-2'-deoxyadenosine 5'-monophosphoryl group (2'-Az-dAMP) from the analogous 5'-

6 erases catalyze the transfer of a nucleoside monophosphoryl group from a nucleotide to a hydroxyl gro

7 CSK4 (TLR1/2 ligand), FSL-1 (TLR2/6 ligand), monophosphoryl lipid (MPL)-A, lipopolysaccharide (LPS, b

8 AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegativ

9 determined that Pg OMVs are enriched for C4' monophosphoryl lipid A (C4'-MPLA), an established agonis

10 yrin-phospholipid (dose, 0.4 ug), along with monophosphoryl lipid A (dose, 0.16 ug) and QS-21 (dose,

11 zation with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) o

12 We previously showed that monophosphoryl lipid A (MLA) activates TLR4 in dendritic

13 l fatty acid chain length in the 3-O-desacyl monophosphoryl lipid A (MLA) series is shown to be a cri

14 e used to achieve early preconditioning, and Monophosphoryl lipid A (MLA) was used to induce late pre

15 Monophosphoryl lipid A (MLA), a nontoxic analogue of end

16 s based on the structure of lipid A, such as monophosphoryl lipid A (MLA), have proven to be safe and

17 phosphoryl lipid A (dLPA) but only weakly to monophosphoryl lipid A (mLPA).

18 ss pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL((R)) ); 51 control patients

19 th either a low or high dose of 3-deacylated monophosphoryl lipid A (MPL) and administered with alum

20 ps were boosted with FI-HSV2 formulated with monophosphoryl lipid A (MPL) and alum adjuvants.

21 in CHO cells and given intramuscularly with monophosphoryl lipid A (MPL) and alum, or gC2 and gD2 we

22 e particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum.

23 the liposome-based AS01 with its components, monophosphoryl lipid A (MPL) and QS-21, and TLR ligands.

24 We previously reported monophosphoryl lipid A (MPL) and synthetic cord factor t

25 from norovirus GI.1 genotype adjuvanted with monophosphoryl lipid A (MPL) and the mucoadherent chitos

26 ype lectin receptor (CLR) agonist pairing of monophosphoryl lipid A (MPL) and trehalose-6,6'-dicoryno

27 The effectiveness of monophosphoryl lipid A (MPL) as a mucosal adjuvant was i

28 ory molecule SA-4-1BBL with the TLR4 agonist monophosphoryl lipid A (MPL) as a novel vaccine adjuvant

29 uble truncated gD protein (gD2t) in alum and monophosphoryl lipid A (MPL) elicited high neutralizing

30 Monophosphoryl lipid A (MPL) from Salmonella typhimurium

31 djuvants microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL) in a murine model of HDM al

32 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

33 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

34 Monophosphoryl lipid A (MPL) is an LPS-derived Toll-like

35 nsisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital herpes dise

36 capsulation of RTS,S in liposomes containing monophosphoryl lipid A (MPL) resulted in a dose-dependen

37 essed whether prophylactic administration of monophosphoryl lipid A (MPL), a nontoxic derivative of l

38 tranasal (i.n.) immunization of rHagB and if monophosphoryl lipid A (MPL), a nontoxic derivative of t

39 e investigated whether nHgbAI dispensed with monophosphoryl lipid A (MPL), an adjuvant approved for u

40 ) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked

41 the nonspecific biological response modifier monophosphoryl lipid A (MPL), given in vivo or incubated

42 Addition of adjuvants, such as monophosphoryl lipid A (MPL), might allow for efficaciou

43 -gp160, formulated with liposomes containing monophosphoryl lipid A (MPL), MPL-AF, proteosomes, emuls

44 ng its superiority to vaccines adjuvanted by monophosphoryl lipid A (MPL)-alum.

45 y in the presence of an additional adjuvant, monophosphoryl lipid A (MPL).

46 (dmLT), when combined with the TLR4 agonist monophosphoryl lipid A (MPL-A), impacted innate and adap

47 ing IP-10) followed by gp140 formulated with monophosphoryl lipid A (MPLA) +QS-21 adjuvant predominan

48 uvant, with microcrystalline tyrosine (MCT), monophosphoryl lipid A (MPLA) and calcium phosphate (CaP

49 ynthetic particulate carriers co-loaded with monophosphoryl lipid A (MPLA) and CpG as pathogen-like p

50 s can be polarized to kill cancer cells with monophosphoryl lipid A (MPLA) and interferon (IFN) y.

51 The strategy, established with a synthetic monophosphoryl lipid A (MPLA) and known MPLA and diphosp

52 A vaccine adjuvanted with deacylated monophosphoryl lipid A (MPLA) failed to protect against

53 Monophosphoryl lipid A (MPLA) is a low-toxicity derivati

54 Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4

55 nal adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or alpha-galactosylceramid

56 th ovalbumin (OVA) and a molecular adjuvant, monophosphoryl lipid A (MPLA) promoted BMDC maturation a

57 ounds 1 and 33 when used as coadjuvants with monophosphoryl lipid A (MPLA) showed significant enhance

58 inked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic

59 (Rha) attached to the 1- and 6'-positions of monophosphoryl lipid A (MPLA) was designed, synthesized,

60 ncapsulated the toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) within hyperbranched polyg

61 Monophosphoryl lipid A (MPLA), a detoxified analogue of

62 Monophosphoryl lipid A (MPLA), a detoxified TLR4 agonist

63 Monophosphoryl lipid A (MPLA), a less toxic derivative o

64 Monophosphoryl lipid A (MPLA), a low toxicity derivative

65 Monophosphoryl lipid A (MPLA), a nontoxic TLR4 ligand de

66 Immunization with these particles and monophosphoryl lipid A (MPLA), a US Food and Drug Admini

67 Surprisingly, monophosphoryl lipid A (MPLA), another TLR4 ligand, enha

68 Priming of mice with LPS, monophosphoryl lipid A (MPLA), or poly(I:C) significantl

69 cts of VTX-294 and R-848 in combination with monophosphoryl lipid A (MPLA; TLR4) were also assessed.

70 ificant levels of Ab reactivity in the NS1 + monophosphoryl lipid A + AddaVax group.

71 bined with aluminum and magnesium hydroxide, monophosphoryl lipid A + AddaVax, or Sigma adjuvant syst

72 we evaluated the effects of adjuvant AS01B (monophosphoryl lipid A [MPL] and QS21), CpG 10105, and t

73 ied in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the abili

74 combinant HSV-2 glycoprotein D (gD2) in alum-monophosphoryl lipid A adjuvant only in HSV women serone

75 e in both flight and ground cohorts received monophosphoryl lipid A alone without additional OVA stim

76 ice with PppA protein and either a synthetic monophosphoryl lipid A analog, RC529AF, or a cholera tox

77 5/50 and 50/50 formulations) adjuvanted with monophosphoryl lipid A and Al(OH)3 We present safety and

78 led to incorporate the amphipathic adjuvants monophosphoryl lipid A and cholesterol-modified CpG olig

79 ose promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger d

80 10)-adjuvanted HIV-1 DNA prime followed by a monophosphoryl lipid A and QS-21 (MPLA+QS-21)-adjuvanted

81 somal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown p

82 ized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the comb

83 -in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (

84 orates two immune stimulants, 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

85 d vaccine adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

86 nd B5R proteins in an adjuvant consisting of monophosphoryl lipid A and trehalose dicorynomycolate or

87 ke particle (VLP) vaccine (with chitosan and monophosphoryl lipid A as adjuvants) to prevent acute vi

88 model of chancroid, using either Freund's or monophosphoryl lipid A as adjuvants.

89 s toxoid and mixed with liposomes containing monophosphoryl lipid A as an adjuvant.

90 in D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant; control subjects

91 In this way, the immunostimulant activity of monophosphoryl lipid A can significantly improve the imm

92 A semisynthetic strategy to obtain monophosphoryl lipid A derivatives equipped with clickab

93 as LPS on aHSCs, indicating specificity, and monophosphoryl lipid A down-regulated fibrogenic markers

94 albumin (OVA) and TLR agonists imiquimod and monophosphoryl Lipid A encapsulated in poly(d,l-lactide-

95 dministration of ADX40-Id with 3-O-deacyl-4'-monophosphoryl lipid A further significantly enhanced va

96 ection induced by Leish-111f formulated with monophosphoryl lipid A in a stable emulsion (Leish-111f+

97 subunit vaccine with alum and 3-O-deacylated-monophosphoryl lipid A in subjects whose regular sexual

98 combination with lipopolysaccharide (LPS) or monophosphoryl lipid A led to strongly synergistic produ

99 stable emulsion (SE) with the TLR4 agonists monophosphoryl lipid A or glucopyranosyl lipid A (GLA) h

100 functions were enhanced after treatment with monophosphoryl lipid A or phosphorylated hexa-acyl disac

101 significantly decreased in mice treated with monophosphoryl lipid A or phosphorylated hexa-acyl disac

102 e conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

103 and rabbits was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

104 terol-rich liposomes containing the adjuvant monophosphoryl lipid A results in the production of anti

105 reas the TLR4 ligands lipopolysaccharide and monophosphoryl lipid A substantially augmented the magni

106 is, which were eliminated by the addition of monophosphoryl lipid A to the formulation.

107 Stimulation with the TLR-4 ligand monophosphoryl lipid A together with IFN-gamma (alt-2 DC

108 Monophosphoryl lipid A was prepared from the lipopolysac

109 with Om-S-MERS-RBD and adjuvants (Alum plus monophosphoryl lipid A) induced broadly neutralizing ant

110 -MPL (aluminum hydroxide plus 3-O-desacyl-4'-monophosphoryl lipid A) induced robust L2 antibodies (EL

111 nosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or

112 For example, monophosphoryl lipid A, a family of endotoxic TLR4 agoni

113 The addition of monophosphoryl lipid A, a minimally toxic derivative of

114 in approved products is AS04, which combines monophosphoryl lipid A, a TLR-4 agonist, with alum.

115 accine candidate, in conjunction with either monophosphoryl lipid A, a TLR4 agonist, or CpG, a TLR9 a

116 stimulator of interferon genes pathway, and monophosphoryl lipid A, and a Toll-like receptor 4 agoni

117 free vaccine composed of aluminum hydroxide, monophosphoryl lipid A, and fungal mannan that improved

118 nt synthesizing an adjuvant form of lipid A (monophosphoryl lipid A, MPLA) displayed increased biogen

119 d with lactated Ringer's (vehicle) solution, monophosphoryl lipid A, or phosphorylated hexa-acyl disa

120 CD14 that functionally affects LPS, but not monophosphoryl lipid A, pro-inflammatory cytokine produc

121 d with alum and the detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the

122 onstrated a lipid-based adjuvant composed of monophosphoryl lipid A, synthetic cord factor, and squal

123 A time course study showed that monophosphoryl lipid A- and 3-deacyl 6-Acyl phosphorylat

124 han the wild-type allergens and a registered monophosphoryl lipid A-adjuvanted vaccine based on natur

125 A1 was combined with commercially available monophosphoryl lipid A-based adjuvant, and after immuniz

126 protein formulated with either Alhydrogel or monophosphoryl lipid A-containing adjuvants resulted in

127 Only mice treated with L110f plus monophosphoryl lipid A-CpG were able to induce a strong

128 erule-derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA va

129 The endogenous production of calcitriol by monophosphoryl lipid A-stimulated DCs appeared to be Tol

130 A monophosphoryl lipid A-Thomson-Friedenreich (TF) antigen

131 by using the combined adjuvant of alum plus monophosphoryl lipid A.

132 co-stimulated with the TLR4-agonist adjuvant monophosphoryl lipid A.

133 OVA) 323-339 plus the inflammatory adjuvant, monophosphoryl lipid A.

134 ) product with MicroCrystalline Tyrosine and monophosphoryl lipid-A as an adjuvant system (Grass MATA

135 adjuvant, Freund's incomplete adjuvant, and monophosphoryl-lipid A/trehalose dicorynomycolate adjuva